International Journal of Clinical Research

Objective To explore the effect of rabeprazole combined with anti-Helicobacter pylori therapy on patients with gastric ulcer. Methods 116 patients with gastric ulcers admitted to our hospital from December 2013 to November 2021 were randomly divided into a control group (58 cases treated with clarithromycin, metronidazole, colloidal bismuth pectin, and omeprazole) and a study group (58 cases treated with clarithromycin, amoxicillin, colloidal bismuth pectin, and rabeprazole). The clinical efficacy, ulcer improvement, inflammation level, and HP eradication rate of the two groups were compared and compared. Results The total therapeutic effect of the observation group was higher than that of the control group (P<0.05); The proportion of active and healing ulcer patients in the observation group was lower than that in the control group, while the proportion of healing ulcer patients was higher than that in the control group (P<0.05); The ulcer area was smaller than that of the control group (P<0.05), and the difference before and after ulcer treatment was greater than that of the control group (P<0.05); The inflammation level in the observation group was lower than that in the control group (P<0.05); The HP eradication rate in the observation group was higher than that in the control group (P<0.05). Conclusion The use of rabeprazole combined with anti Helicobacter pylori treatment in patients with gastric ulcers can provide better therapeutic effects, improve ulcer conditions, and reduce inflammation levels.

Gastric ulcer; Anti-helicobacter pylori; Rabeprazole